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Written instructions for at home management of OIT.
Instructions
 Do not take the dose with empty stomach
 Avoid going to bed at least in the two hours after the dose
 Avoid exercise or sport activity for at least 2 hours after food intake
 If infections, asthma exacerbation, gastrointestinal diseases, / or menses: reduce or
stop the dose of foods during acute phase, at least for 3 daysTo the Editor,
Oral immunotherapy (OIT) can effectively induce a clinical desensi-
tization in patients with persistent IgE-mediated food allergy (FA) to
cow's milk (CM), hen's egg (HE), and peanut allergy.1,2 However, its
safety remains one of the major concerns, as adverse reactions (ARs) are
quite frequent, unpredictable and unexpected.1,2 ARs can occur with a
previously tolerated dose of the offending food during the maintenance
phase of desensitization, usually managed at home, and mainly during
exercise,3 viral illness or suboptimal asthma control.4
To assess the impact of a specific counseling and a specific written
plan to avoid or reduce ARs occurrence during the maintenance regimen,
we performed a retrospective cohort study. We collected retrospectively
the clinical records of all the children who received OIT for CM or HE
allergy at the Pediatric Allergy Unit of the University of Messina (Italy).
We divided the population into two groups: Group A (n ¼ 62), success-
fully desensitized between 2004 and 2012 but not receiving specific
counseling and written plan about the possible ARs -due to the lack of
knowledge on ARs at that time- and Group B (n ¼ 34) successfully
desensitized between 2013 and 2016, receiving counseling and a written
plan on how to avoid or reduce ARs during the home-based maintenance
regimen (Table 1). All the participants were eligible for OIT, according to
clinical history, persistence of FA symptoms over time, and documented
IgE-sensitization to CM or HE. The OIT protocols used and the follow-up
modalities are reported elsewhere.5,6 Briefly, food dose was weekly
increased until the maintenance dose was achieved. This build-up phase
was always performed in our Unit under medical supervision. Then, the
maintenance phase was carried out at home. The OIT procedure and the
risks of ARs were explained in detail to patients and their families. All
procedures were approved by the ethical review board of Medical Uni-
versity of Messina (Messina, Italy) and a written informed consent was
obtained from parents or legal guardians. The patients and caregivers; FA, food allergy; HE, hen's egg;
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emergency action plan, medications for self-treatment (corticosteroids,
H1-antihistamines, short-term beta2agonist) and adrenaline
auto-injector. Our clinical records, as per protocols, reported in detail:
demography, diagnostic procedures, prescription, discontinuation and
reason for, type and severity of ARs.7,8
Data were summarized as numbers (n) and frequencies (%) if they
were categorical and as mean/median and standard deviation (SD)/
interquartile range (IQR) if quantitative. A paired Student t-test was used
to compare the two groups and timing. These statistical tests were con-
ducted using Prism software, version 6.0 (GraphPad, La Jolla, CA, USA).
A P-value<0.05 was considered statistically significant.
Overall, 96 children underwent OIT for CM or HE. Group A included
62 patients, 35 desensitized for CM and 27 for HE between 2004 and
2012 (18 male, age range 4–13 years) and Group B included 34 patients,
10 desensitized for CM and 14 for HE between 2013 and 2016 (17 male,
age range 4–14 years) (Table 2). No significant baseline differences were
in age, food-specific IgE levels, skin test results, or oral food challenge
(OFC) results between groups (Table 2). In Group B, there was a signif-
icant reduction in ARs versus Group A during the maintenance phase
(p ¼ 0.002). Before the introduction of counseling and written plan, 13/
62 patients (21%) in Group A had mild to severe ARs during sportIQR, interquartile range; OFC, oral food challenge; OIT, oral immunotherapy; SD,
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Table 2
Characteristics of study population.
Group A (n ¼ 62) Group B (n ¼ 34)
Cow's milk Hen's egg Cow's milk Hen's egg
Median/n IQR/% Median/n IQR/% Median/n IQR/% Median/n IQR/%
Patients (n,%) 35 56 27 44 20 59 14 41
Male (n,%) 18 29 15 24 11 32 6 18
Age (y) (mean  SD) 8.9  2.3 7.3  2.6 7.9  2 7.7  2
Caucasian (n, %) 35 56 27 44 20 59 14 41
Other allergic comorbidities
Additional food allergies (n, %)a 3 5 6 10 1 3 3 9
Allergic asthma (n, %) 11 18 7 11 6 18 4 12
Allergic rhinitis (n, %) 10 16 11 18 7 21 5 15
Atopic dermatitis (n, %) 7 11 4 6 3 9 2 6
Food specific data
Baseline IgE (kU/L), median (range)b 32.5 (8.2-126) 36.5 (5-110) 25.8 (5.5-98) 38.5 (4.3-98.6)
Baseline SPT wheal diameter (mm), median (range)b 7 (5-15) 11 (7-20) 7 (5-16) 9 (6-17)
Baseline OFC successfully consumed dose (mg), median (IQR)b 13.2 (0-105.6) 0.8 (0-100) 6.6 (0-105.6) 1.5 (0-100)
Clinical presentation (baseline OFC)
Anaphylactic shock (n, %) 8 13 9 15 4 12 5 15
Asthma (n, %) 9 15 6 10 5 15 4 12
Diarrhea (n,%) 4 6 4 6 2 6 3 9
Rhinitis (n, %) 17 27 11 18 10 29 7 21
Urticaria (n, %) 15 24 19 31 9 26 10 29
Vomiting (n,%) 10 16 13 21 5 15 5 15
AR(s) during maintenance phase
Mild-moderate ARs (n, %) 4 6 0 0 1 3 0 0
Mild-moderate ARs per patient, median (IQR) 3 (2.25-4.5) 0 (0-0) 0 (0-0) 0 (0-0)
Severe ARs (n, %) 5 8 3 5 0 0 0 0
Severe ARs per patient, median (IQR) 2 (1-2.5) 3 (2-5) 0 (0-0) 0 (0-0)
Eosinophilic Esophagitis (n,%) 1 2 0 0 0 0 0 0
Total Patients with ARs (n, %)c 10 16 3 5 1 2 0 0
Data were summarized as numbers (n) and frequencies (%) if they were categorical and as mean/median and SD/IQR if quantitative.
All characteristics were not statistically significantly different between groups and subgroups.
AR, Food-related adverse reaction; IQR, Interquartile range; OFC, oral food challenge; SPT, skin prick test.
a Includes egg (when different from OIT food), milk (when different from OIT food), tree nuts, fish, and wheat.
b Values referred to cow's milk or hen's egg according to the respective group.
c P values were statistically significant for comparisons between total patients with ARs (group A vs group B, p ¼ .002); cow's milk and hen's egg subgroups were
combined for the analysis.
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seling and written instructions (2013–2016), the rate fell to 1/34 (3%)
(p ¼ 0.002) (Table 2). Within Group B, 18 patients (53%) had regular
sport activity, five girls (15%) completed the pubertal stage, 20 (59%)
suffered from acute infections (18 upper and/or lower respiratory tract, 1
skin, 1 urinary tract), but no severe ARs was reported. Only one patient in
Group B, during OIT maintenance reported abdominal pain and gener-
alized urticaria after sport activity. He ate 150 mL of milk 1 h before
playing football. After this single episode, he continued the maintenance
protocol. Of note, one of those patients desensitized to CM, during
maintenance phase had frequently nausea, vomiting, dysphagia. An
endoscopic biopsy specimen of the upper digestive tract showed a
cellular infiltrate (>20% of eosinophils) in the esophageal epithelium,
with intracellular edema and basal zone hyperplasia. In the two groups,
only this patient had to stop the maintenance phase because of the
diagnosis eosinophilic esophagitis.
The percentage of patients who successfully complete an OIT course
and who achieve a full tolerance ranges between 35% and 100%.7,8 Thus,
safety remains a major concern of the procedure. It is currently not clear
if a prolonged intake of the responsible food is needed to maintain
tolerance, and in such cases the maintenance (regular assumption) is
obviously managed at home, with possible additional safety problems.
However, the so called “ad libitum diet” may be unpleasant above all for
uncommon food. The frequency and grading of ARs during the up-dosing
regimen was previously assessed,8 but ARs can occur also during main-
tenance phase.1,2,8 In addition, the setting of infection, sport exercise or
menses are described frequent causes of acute ARs, or temporary relapse
of FA during the maintenance or post-desensitization phases.1–4 In the
present report, we evaluated if an adequate counseling could reduce the
ARs occurrence during the maintenance phase. The occurrence of ARs2
decreased from 21% to 3%, when written instructions were regularly
given. Overall, only one patient out of 34 who received the instructions
had moderate ARs, and none discontinued OIT. A limitation of this study
stands in the retrospective study design, partly justified by the fact that
the risk factors were identified only “a posteriori”. However, data are
complete, since, according to OIT protocols, they were accurately
collected and patients regularly attended follow-up visits. In the present
retrospective analysis, we confirm that ARs during post-desensitization
phase of OIT can be minimized by providing few simple written in-
structions. These include avoiding physical activity within 2 hours of
food intake, and reducing or interrupting the food intake during febrile
illness. As per good clinical practice, all patients should be provided with
an emergency action plan and auto-injectable adrenaline. Asthma, when
present, should be adequately controlled with standard of care therapy.9
With proper information and a structured written instruction plan, the
risk of possible adverse reactions during the maintenance phase of food
desensitization can be significantly reduced, still maintaining the bene-
ficial effect of treatment.Clinical implicationSafety is one of the major concerns of oral immunotherapy for IgE-
mediated food allergy.
Proper information and a structured written instruction plan can
significantly reduce the risk of adverse reactions during the
maintenance phase of oral immunotherapy, still maintaining the
beneficial effect of treatment.
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